Skip to content

RNAM

Avidity Biosciences, Inc.

NASDAQ · Healthcare · Biotechnology · US

$72.86
+0.05%
Ask drillr

Year over year

Reported trailing growth

Revenue
+72.1%
EBITDA
-97.2%
EBIT
-96.9%
EPS
-71.0%
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
—

Three-year CAGR

Revenue
+26.7%
EBITDA
-97.2%
EBIT
-96.9%
Net income
—
EPS
-72.0%
Free cash flow
—

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026